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Panton Valentine Leucocidin (PVL), a pore-forming cytotoxic secreted toxin, has been 
associated with severe Staphylococcus aureus pneumonia and prototypical skin lesions. The 
reported incidence and prevalence of PVL-positive S. aureus (PVLPSA) varies globally and 
suffers from a selective reporting bias towards community associated MRSA (CA-MRSA). 
Recent studies, however, have identified PVL-positive methicillin-susceptible S. aureus 
(MSSA) more frequently than previously expected. In this review, a group of experts from 
four continents affiliated with the International Society of Chemotherapy offer a position 
statement on the important aspects of PVL in S. aureus epidemiology, antimicrobial 
treatment, and decolonisation, and aims to highlight future areas for collaboration and 
research.  
 
1) What is Panton-Valentine Leucocidin (PVL)? 
 
PVL belongs to a family of synergo-hymenotropic toxins which consist of two non-
associated components acting synergistically on cell membranes. The toxin is encoded by the 
lukS-PV and lukF-PV bacteriophage transmitted genes whose detection is used in 
epidemiological studies to detect and determine the prevalence of PVLPSA [1].  
 
The main PVL cellular targets are polymorphonuclear leukocytes, monocytes and 
macrophages. PVL binds to complement receptors on the membranes of these cells and 
induces membrane channel formation leading to cell destruction. The toxin also induces the 
release of pro-inflammatory cytokines and nuclear factor-kappa B in neutrophils and is an 
important virulence factor in necrotizing infections [2]. In PVLPSA pneumonia the risk of 
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death has been reported to be higher than with non-PVL-producing S. aureus (PVLNSA) [3]. 
PVL has also been identified in S. haemolyticus and S. simulans [2]. 
 
Outbreaks of PVLPSA were initially reported in MSSA in the mid twentieth century [4]. In 
the 1990s PVL was reported in the “newly” emerging CA-MRSA [5, 6], with ST8/USA300 
becoming the predominant PVL-producing clone in the USA, ST80 in Europe, ST59-V in 
Asia, ST30 in the Asia Pacific,  and ST93-IV in Australia [7]. However not all CA-MRSA 
produce PVL. Furthermore the toxin is not exclusive in the success of some CA-MRSA 
clones and consequently there is conflicting data regarding the role of PVL in the 
pathogenesis of CA-MRSA infection.  PVL+ve MSSA, which produce a similar clinical 
presentation as PVL+ve MRSA, is thought to be a potential reservoir for the emergence 
of PVL+ve CA-MRSA [8, 9]. 
 
 
2) Overview of  the global prevalence of PVL in S. aureus 
 
Globally, the reported incidence of PVLPSA is variable and its presence is strongly attributed 
to strain types/lineages. Unlike local and national reference centres, diagnostic microbiology 
laboratories do not routinely test for PVL. When testing is performed it is often based on a 
clinician, microbiologist or an infectious diseases specialist request and tends to favour 
MRSA, in particular CA-MRSA, and isolates from severe S. aureus infections. In most 
places PVL testing on MSSA is not routinely performed.  Consequently the reported 
prevalence of PVL is largely inaccurate and/ or underrepresented.  
 
The proportion of PVLPSA and PVLNSA that are methicillin resistant varies.  Some studies 
have shown the prevalence of PVLPSA is the same for MSSA and MRSA and the prevalence 
of PVL-positive CA-MRSA is the same as PVL-negative CA-MRSA [10, 11].  However in 
other studies all PVLPSA were methicillin sensitive and approximately one third of  
PVLNSA were methicillin resistant [12]. Conversely, in other studies, when compared to 
PVLNSA, a greater proportion of PVLPSA were methicillin resistant [13, 14]. 
 
A strong epidemiologic association has been found in the USA between SSTIs and the 
PVLPSA USA300 MRSA strain. For example, in a large study in 2004, 78% of S. aureus 
from SSTI were MRSA, among which 98% were USA300 with nearly all of them PVL+ ve 
[15]. In another study in the USA, of 1,055 S. aureus causing various infections, 36% were 
PVL+ve, there was a high level of methicillin resistance (78% of all isolates), a higher level 
of PVLPSA amongst MRSA than amongst MSSA (48% vs 11.5%), and a higher level of 
methicillin resistance among PVLPSA isolates than among PVLNSA isolates (89.1% vs 
53.5%).The differences were even more pronounced amongst isolates causing SSTI [13]. The 
prevalence of PVL+ve MRSA isolates from SSTIs in China has been reported to be as high 
as 19% [16].  A longitudinal study investigated the transmission of S. aureus between 
mothers and their newborns showed high prevalence of USA300-related S. aureus among 
MRSA isolates with 56.7% of all S. aureus carried PVL encoding genes [17]. Detection of 
nasopharyngeal PVLPSA colonization in 0.22% of patients without SSTI admitted to a UK 
hospital implies that PVLPSA carriage can be asymptomatic, in a country with a low 
prevalence of CA-MRSA infections [18]. 
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Overall robust global epidemiological data on PVLPSA is lacking. Driven by the availability 
of laboratory facilities and selective testing, international collaborative studies are warranted 
to determine the true incidence and dynamics of PVLPSA.   
 
 
3) Overview of main clinical presentations associated with PVLPSA  
 
Recurrent SSTIs are the hallmark clinical syndrome of PVLPSA. For example in a large USA 
study performed in 2004, 78% of S. aureus from SSTI were MRSA, of which 98% were due 
to the PVL-positive USA300 clone [15]. In a Chinese study the prevalence of PVL+ve 
MRSA isolates from SSTIs was reported to be as high as 19% [16]. Although in furunculosis 
up to 93% of S. aureus strains are PVL positive, PVLPSA are less frequently isolated in 
abscesses, cellulitis and finger pulp infections [19].  
 
PVLPSA SSTI often has distinctive features when compared to PVLNSA SSTIs : I) often no 
portal of entry is identified, hence the classification as ‘primary’ skin infection. However, 
disruption of the skin barrier (e.g., chronic skin disease, scabies, minimal trauma, insect bites, 
shaving) can facilitate the infection; II) lesions tend rapidly to become extensive; III) the risk 
of transmission within households, or to other close contacts, is particularly high; and IV) 
recurrence is frequent [20].  
 
The clinical spectrum of PVLPSA however is much broader than just SSTIs, ranging from 
asymptomatic nasopharyngeal colonization [18] to fatal necrotizing pneumonia [3]. As with 
other coagulase-positive staphylococci, nasal carriage is a risk factor for PVLPSA infections 
[21]. 
 
PVLPSA can be isolated in the majority of patients with community-acquired necrotizing 
pneumonia, among whom mortality ranges from 40 to 60% [19]. PVLPSA pneumonia 
usually occurs in children and young adults, without comorbidities, and tends to be preceded 
by an influenza-like prodrome [3]. The pneumonia is characterized by the rapid onset of fever 
and hemoptysis. This rapidly progresses to acute respiratory distress syndrome (ARDS) and 
septic shock, often requiring mechanical ventilation and circulatory support. Leucopaenia is 
common. Radiology shows rapidly progressive multilobar consolidation, pleural effusions 
with cavitary infiltrates.  
 
PVLPSA are also associated with severe musculoskeletal infections, particularly in children. 
The main characteristics of the infection include long-term fever, high levels of inflammatory 
markers and high frequency of complications leading to longer stays in intensive care units 
and a more frequent need for surgical treatment [22]. 
 
 
4) PVL on the move  
 
Although defence mechanisms against phage infections in S. aureus have been described, 
including three restriction modification systems [23] and clustered regularly interspaced short 
palindromic repeats (CRISPR) loci [24], the PVL-associated genes, lukS-PV and lukF-PV, 
have been identified in many S. aureus genetic backgrounds including clonal complex (CC)1, 
CC5, CC6, CC8, CC22, CC30, CC45, CC59, ST772, CC75, CC80, CC88, CC93, CC121, 
CC152, ST154, CC398, ST1349, CC942 and ST2563 [25-34] 
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lukS-PV and lukF-PV, are located on several temperate Siphoviridae phages including 
φSa2958, φSa2MW, φPVL, φ108PVL, φSLT, φ7247PVL, φSa119, φTCH60 and φSa2USA 
[25, 26, 35]. This family of double-stranded DNA viruses shares a long noncontractile tail 
and capsid with an isometric or an elongated shape [35]. The PVL-associated phages belong 
to group 1 (isometric head type), group 2 (elongated head type) or group 3 of Sfi21-like cos-
site Siphoviridae [35,36]. More variation in the phages carrying the PVL-associated genes is 
found in MSSA than in MRSA [26]. Phages in S. aureus can be induced as a consequence of 
antibiotic treatment with tobramycin, ciprofloxacin, trimethoprim/sulfamethoxazole 
(TMP/SMX), imipenem or trimethoprim [37-39], which in turn may facilitate the 
transmission of PVL-carrying phages among the S. aureus population.  
 
Several PCR-based typing systems have been developed to identify the different PVL+ 
phages [26, 40]. However these systems are not on their own very useful for outbreak control 
and epidemiological use. A study found extremely small variation among CC80 outbreak or 
non-outbreak isolates hence the pahge type may only reflect the CC background [41]. Genetic 
analyses of the S. aureus host is required if it is crucial, for example, to distinguish between a 
highly transmissible PVLPSA strain and a PVL+ phage that is spreading among S. aureus.  
 
 
5) Antibiotics and their effect on PVL production 
 
It has been known for some time, when incorporated into culture media at sub minimal 
inhibitory concentrations (sub-MIC) antibiotics are capable of modifying the metabolic 
processes of bacteria  [42]. The antibiotic can induce modulation of virulence factors which 
may lead to either aggravation or attenuation of an infection.   
 
As some of the products of virulence-associated genes can be measured, it is possible to rank 
individual antibiotics in order of their effect upon toxin production. In vitro findings suggest 
clindamycin, linezolid and fusidic acid inhibit PVL production, vancomycin has little or no 
effect, and sub-inhibitory concentrations of oxacillin and other β-lactams enhance PVL 
production [43 ,44]. Antibiotics binding to penicillin binding protein 1 (PBP1)  increases 
PVL expression by modulating sarA and rot, which are essential mediators of the inductor 
effect of β-lactams on PVL expression [44]. 
 
 
Clindamycin and linezolid are inhibitors of protein synthesis and are therefore likely to 
inhibit the synthesis of S. aureus structural proteins and enzymes. Exposure to linezolid even 
at sub-MIC levels has been shown to reduce spa gene expression, increasing the 
susceptibility of S. aureus to phagocytosis by human neutrophils [45], which provides a 
plausible explanation why linezolid may be ideal for the management of aggressive or 
invasive PVLPSA infections. This action of clindamycin is not clearly understood [46]. 
 
 
As bacterial exposure to sub-MIC of antibiotics under clinical conditions is plausible, 
particularly within biofilms and necrotic tissues, one can argue β-lactam antibiotics should be 
avoided in PVLPSA infections. However, the in vivo clinical significance of  PVL production 
enhancement using β-lactam antibiotics is unknown. Therefore unless there are features of 
severe infection with necrosis patients should be commenced on β-lactam antibiotics, at least 
at the empirical stage of therapy. In severe PVLSPA infections it is prudent to give antibiotics 
at the highest safest dose at regular intervals to avoid a drop in concentration to sub-MIC 
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5A) Antimicrobial treatment strategies for SSTI associated with PVLPSA 
 
The most appropriate management of SSTIs with purulent collection is represented by the 
surgical drainage of the purulent collection/ abscess. In the case of uncomplicated SSTI there 
may be no need for the use of systemic antibiotics. Localised lesions without systemic 
features may be managed with topical antimicrobial therapy. However a recent trial involving 
>1200 patients with a drained cutaneous abscess, (majority due to USA300 CA-MRSA), 
demonstrated patients who received TMP/SMX (1920 mg twice daily, for 7 days) had a 
higher cure rate than those who received a placebo. Additionally there were fewer subsequent 
surgical drainage procedures, new skin infections, and infections among household members 
in the TMP/SMX group than in the placebo group [47].  
 
To our knowledge there are no published clinical data to support treating non necrotic 
PVLPSA infections with anti-PVLPSA antibiotics. Consequently unless there is a high 
prevalence of methicillin resistance standard therapy with adequate doses of anti-
staphylococcal β-lactams should be the primary choice. In times of rising antimicrobial 
resistance and greater need for antibiotic stewardship this approach should be the aim in 
clinical practice. Apart from in severe necrotic cases, combination therapy is seldom 
required. Choice of antibiotics (table 1) will depend on local epidemiology and national 
guidelines. In severe infections with features of toxic shock, necrotising fasciitis, or purpura 
fulminans there may be a theoretical case for using two or three agents with or without 




 5B) Antimicrobial treatment strategies for bone and joint infections (BJI) associated 
with PVLPSA 
 
In bone and joint infections (BJI), concentrations below the MIC may occur because of poor 
antibiotic penetration, especially in the presence of necrosis associated with PVL. Hence, an 
effective antimicrobial treatment for PVLPSA associated BJI should include antibiotics 
inhibiting protein synthesis. This would be particularly important when using β-lactams or 
vancomycin in necrotic tissues. The use of linezolid alone for BJIs could be effective, but it is 
limited by its potential toxicity in prolonged therapy (4-6 weeks) which is often necessary. 
The use of rifampicin alone is strongly not recommended due to the risk of selecting resistant 
isolates with a high inoculum.  
 
The pattern of antimicrobial susceptibilities of the etiological agent has to be considered for 
the selection of the most appropriate antibiotic treatment. If the infection is caused by PVLP-
MSSA, the highest possible dose of flucloxacillin (or equivalent semisynthetic β-lactamase-
resistant penicillin) with clindamycin could be combined. For suspected or proven PVL+ve 
MRSA, several antimicrobial regimens could be administered (Table 1). The combination of 
linezolid and vancomycin is not recommended because of potential antagonistic effect [50]. 
The new agent tedizolid may prove useful for PVLPSA BJI infections, but data to support its 
use are still lacking. Once again national and local guidelines should be followed. Off-label 
use of antimicrobials with favourable pharmacological and microbiological characteristics 
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(e.g., good bone penetration and optimal activity against MRSA), such as daptomycin and 
linezolid, is frequently necessary. 
 
 
5C) Antimicrobial treatment strategies for pneumonia associated with PVLPSA  
 
In cases of suspected or confirmed PVLPSA pneumonia, in addition to physiological support, 
it is crucial to commence appropriate antimicrobial therapy (often combinations) without 
delay. Initial empirical coverage against S. aureus should be initiated, for example, when S. 
aureus pneumonia is suspected or during influenza season, followed by targeted therapy 
when culture results are available.  
 
In cases of fulminant PVLPSA pneumonia, it is recommended inhibitors of toxin production 
such as clindamycin, linezolid, or rifampicin is included in the regimen. Combinations of 
vancomycin with clindamycin or rifampicin, or rifampicin with linezolid or clindamycin have 
demonstrated success [51-53]. Early in the disease period adjuvant therapy with IVIG can be 
considered,  for toxin neutralisation [54] although the evidence is still limited. Intensive care 
support is often required and extracorporeal membrane oxygenation (ECMO) may be 
considered early during therapy [55]. To our knowledge there are no reports demonstrating a 
clinical benefit of corticosteroids in PVLPSA pneumonia.  
 
6) Eradication of MRSA/MSSA and recurrent colonisation (why, what are the risk factors, 
what should we do?) 
 
Decolonisation is part of a process to completely remove or eradicate bacterial colonisation 
(eradication), or to reduce its bioburden (bioburden reduction). 
 
In countries with a “Search and Destroy” policy, the detection (search) of MRSA is followed 
by the eradication (destroy) protocol. The goal of “Search and Destroy” is to reduce the 
chance of introducing and spreading MRSA into health care facilities. In Denmark 
eradication always involve treating all household members. In other countries treatment of 
household members is dependent on the individual situation i.e. repeated infections in more 
than one household member, a case of necrotising pneumonia, or where contacts are in a high 
risk group for transmission (e.g. healthcare workers). Although various periods of long-term 
follow up are used in different countries, declaring successful eradication usually requires 
multiple negative culture-sets, at different time points [56-58].  
 
 
Bioburden reduction, as opposed to eradication, is the goal of decolonisation therapy in 
certain cases, e.g., prior to an operative procedure, recurrent SSTI, and decreasing the risk of 
transmission to others.  
 
Various agents and strategies have been used to eradicate S. aureus colonisation; however the 
optimal schedule has yet to been defined. Most studies are not focused on known PVLPSA 
carriers. Perl et al [59] and Bode et al [60] showed intranasal application of mupirocin in 
carriers [54] or in combination with chlorhexidine body wash [60] significantly decreased the 
rate of nosocomial S. aureus infections. Clinical evidence on methods for S. aureus 
eradication from the mouth is lacking. Because environmental surfaces serve as reservoirs, 
the implementation of cleaning is recommended as part of regimens to eradicate body 
colonization. Studies evaluating the use of systemic antibiotics in eradicating S. aureus 
Page 7 of 23
produced conflicting data with emergence of antimicrobial resistance and toxicities being 
reported. Therefore treatment with systemic antibiotics for decolonisation is limited to 
particular circumstances [61-63].    
 
Failure of eradication or re-colonisation can occur even after multiple decolonisation 
attempts. This has been associated with non-compliance with the decolonisation regimen, 
active wounds, presence of devices, chronic pulmonary diseases and colonisation of extra 
nasal sites (e.g., throat, gastrointestinal tract) or re-colonisation from a close contact. In 
addition, resistance to agents used for topical decolonisation has been associated with 
persistent S. aureus carriage [64], a factor that needs to be considered before implementing 
widespread use of eradication therapies.  
 
Although the optimal decolonization therapy for PVLPSA is not known, it is likely to be 
similar to those used for MRSA decolonisation. Recommendations regarding decolonisation 
for PVLPSA vary by geographical region and are generally adapted from MRSA eradication 
regimens. In the USA, where PVL+ve MRSA is relatively common, eradication therapy is 
only considered once other hygiene measures have failed. In contrast, a more aggressive 
approach of eradication for cases and contacts (after a risk assessment) is taken in England 
and Scotland where PVLPSA disease is relatively rare [65 , 66]. Although practiced in some 
countries, limited data support performing initial eradication in all household members [58]. 
In eradication failure, particularly where no cause was identified, it is generally not 
reasonable to perform more than five standard decolonization attempts. In such cases 
treatment of underlying conditions (skin disease or change of devices) should be optimized 
and simultaneous treatment of the index patient and household contacts is recommended. 
Extended decolonization regimens over three months with intranasal mupirocin on five 
consecutive days each month and antimicrobial baths two to three times per week have been 
proposed [67]. Further studies are required to support this approach. Systemic antibiotics may 
be considered [47, 61-63].  
 
Further research will better inform clinical and public health measures to control PVLPSA. In 
the era of increasing antibiotic resistance, future research is also urgently required on non-
antibiotic strategies in eradication of PVLPSA and other S. aureus, e.g. application of UV 
light, Reactive Oxygen Surgihoney (SHRO), probiotics and others.   
 
 
7) PVLPSA infections in pets and zoonotic cross infections: what can be done? 
 
Although dogs and cats are not natural reservoirs for S. aureus, they can become colonised.  
For example MRSA colonisation frequently occurs while living in close contact with human 
MRSA carriers [68]. Cefai et al, reported isolation of an MRSA with an identical phage type 
from the nose of a health care worker, his partner and their pet dog [69] . While another 
report demonstrated recurrence of the MRSA infection of a couple only stopped once their 
pet dog was no longer an MRSA carrier [70]. Transmission of MRSA between humans and 
horses has also been suspected in veterinary settings [71].  
It is widely recognized, because of the close contact with humans, companion animals tend to 
share the same lineages identified in humans. Consequently, pets may become reservoirs of 
PVLPSA in regions with high PVL prevalence in the human S. aureus population. Three 
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studies have reported a likely role of the household pet in human PVL+ve MRSA carriage 
and infection. In two studies, the patient’s cure and decolonization required treatment of all 
“family members” (including the pet) with ciprofloxacin and rifampin [68, 72]. However, a 
recent case report on the dynamics of household transmission of MRSA USA300 by whole 
genome sequencing failed to implicate the pet in human MRSA outcomes [73].  
According to European Union guidelines [74], companion animals for which clinical 
infection with MRSA is suspected or confirmed should be monitored and quarantine 
considered. It has been recommended MRSA-infected pets should be restricted from human 
contact until clinical cure [75]. As for healthy pet carriers, there is currently insufficient 
evidence to recommend routine decolonization. Rigorous hygiene measures should be taken, 
where possible combined with temporary isolation to ease cleaning and disinfection. Testing 
pets of MRSA-positive owners who failed decolonization should be considered if there is a 
specific plan for the pet’s decolonization or short-term removal from the household while the 
humans are being treated [75]. To our knowledge PVL has not been identified in a bona fide 
livestock associated strains. Studies of CC398 strains have pointed to distinct groups: a 
livestock clade (PVL negative) and a human clade (can be PVL+ve). PVL+ve CC398-MRSA 
belonging to the human clade has been identified, particularly in China and surrounding 
countries [76].  
 
 
8) Outbreak management in hospitals/ barracks/ prisons etc. 
 
8A) Managing PVLPSA clusters in hospitals 
 
Clusters of PVLPSA infections or colonization are rare (or not reported) in hospitals. 
However, hospital patients often suffer from comorbidities rendering them prone to serious 
infection. In regions with a single predominant strain type of PVLPSA defining a cluster is 
difficult. Table 2 gives an overview on possible strategies one should consider facing a 
PVLPSA cluster in a hospital.  
 
Most of the reported PVLPSA hospital clusters are MRSA involving pediatric or neonatal 
intensive care units [77-80].  However in this setting MSSA would often be regarded as part 
of the normal flora and would not be tested for PVL. Alongside ST8 (USA300), there are 
reports of other PVL-positive MRSA clones causing clusters of PVLPSA infections or 
colonisation including, ST80 (European community MRSA clone), ST22, ST772 (Bengal 
Bay MRSA)  and ST30 (Southwest Pacific or Oceanic clone). A multicenter study from 
France showed lineages varied by geographical origin, suggesting multiple independent 
clusters. Some patients suffered from necrotizing pneumonia or sepsis, but most clinical 
isolates were from SSTIs. Even though PVLPSA prevalence among SSTIs was high, only a 
few of the PVLPSA-colonized patients subsequently showed signs of an infection [80].  
 
The PVLPSA transmission routes within hospital clusters are not completely understood. In 
most clusters, HCWs were found to be colonized or infected with the cluster strain [77, 79]. 
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Very few environmental investigations detected the respective strains, leaving the 
transmission route unknown [77]. However, application of bacterial whole-genome 
sequencing in real time has been shown to help in identifying carriage by a HCW as a 
potential source of an ongoing MRSA outbreak and directly inform infection-control 
interventions [81]. Transmission is normally limited to close physical contact. Therefore, 
targeted decolonization of colonized patients and staff is important. Nonetheless, escalating 
general hygiene measures such as contact isolation and improved hand hygiene compliance 
and cleaning the environment are the most successful interventions.  
 
 
8 B. Outbreak management associated with community institutions 
 
Community outbreaks have been reported in multiple settings (Table 2), and commonly occur 
in situations where risk factors for S. aureus transmission are present. Risk factors include: 
closed crowded communities where frequent skin-to-skin contact occurs with others who are 
colonized or infected; the presence of compromised skin integrity such as lacerations, 
abrasions or tattoos; sharing of contaminated items or equipment that have not been cleaned 
or laundered between users; and lack of cleanliness. Such settings include athletic gyms used 
by sports teams, military barracks, correctional facilities amongst prison inmates and guards 
[82-84] and close contact sports, e.g., wrestling, rugby, or judo. Many PVLSPA patients 
however may have no identifiable risk factors.  
 
 
8C) Managing household outbreaks of PVLPSA. 
 
Household (or family) outbreaks of PVLPSA have been reported. Outbreaks usually become 
evident when one or more family member presents to their general practitioner or hospital 
with recurrent SSTIs. In general PVLPSA isolates are more likely to generate SSTIs among 
household contacts compared to PVLNSA isolates. A summary of PVLPSA outbreak 
management in hospitals, community settings and among households is presented in Table 2. 
 
 
9) The role of cleaning and decontamination for controlling PVLPSA in healthcare and 
community settings 
 
People colonised or infected with PVLPSA contaminate the items that they touch, and shed 
the organism into the air. Onward transmission to additional surfaces will be facilitated by 
dust via air currents and by hand contamination [40]. PVLPSA will persist for months, even 
in dry environmental niche, and therefore need to be removed by cleaning or disinfecting.  
  
Community institutions facing particular risk from PVLPSA transmission include private 
homes, nursing and residential homes, military barracks, prisons, hostels for students and 
homeless, orphanages, youth correctional facilities, sports centres and swimming pools. 
Schools, youth clubs, nurseries, brothels, shopping centres, public transport, cinemas and 
theatres may also have environmental contamination. Persistent colonization of companion 
animals may represent an additional source for human colonisation, however data remain 
scarce in this field (please see section 7) . Members of staff at healthcare facilities treating 
people with PVLPSA carriage or infection are themselves at risk [85-88].
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Similar control methods apply to the majority of these institutions. Personal protection starts 
with hand hygiene, followed by cleaning and decontamination of the environment, including, 
frequent hand-touch sites in wards, kitchens, toilets, bathrooms, changing and treatment 
rooms. Cleaning practices should first focus on physical removal of dirt and debris using 
detergent-based methods. Disinfectants may be applied to high risk sites, provided the agent 
chosen is effective against S. aureus. Floors and other surfaces would also benefit from 
disinfection in isolation rooms and multi-bedded areas, particularly if there is evidence of 
ongoing PVLPSA transmission. Automated decontamination devices dispelling hydrogen 
peroxide (H202) and UVC micro biocidal light, although costly, may be employed in the 
terminal cleaning of vacated single rooms, but not communal areas [89]. Comprehensive 




10)  Chlorhexidine resistance in S aureus   
 
The intensive use of chlorhexidine has been associated with reduced susceptibility in 
healthcare-associated S. aureus and coagulase negative staphylococci (CoNS). The resistance 
mechanism widely implicated is the expression of transmembrane pumps which efflux 
chlorhexidine in exchange for protons. Such efflux pumps are primarily encoded by qacA/B 
genes which are present on large conjugative plasmids carrying multiple determinants of 
resistance to antibiotics and other biocides [90, 91]. This raises a concern of potential cross-
resistance between chlorhexidine and antibiotics as well as inter-strain and inter-species 
horizontal transmission of multidrug resistance plasmids. Nonetheless, the clinical 
significance of qacA/B carriage itself remains unclear. While many studies report minimal 
qacA/B carriage in MRSA over sustained periods of time in intensive care settings, others 
continue to report high qacA/B carriage and reduced susceptibility to chlorhexidine in S. 
aureus and CoNS [91, 92]. Recently, qacA/B carriage has also been reported in PVL+ve 
MSSA from osteomyelitis and necrotising pneumonia [92]. While there are no reports of 
qacA/B carriage in PVL+ve MRSA, this trend may well change as the prevalence of hospital-
associated PVLPSA strains increases.  
 
In S. aureus, mutations of the promoter region of norA have been implicated in potential 
cross-resistance of chlorhexidine and fluoroquinolones [93, 94]. Randomised controlled trials 
to measure the effect of chlorhexidine-based strategies versus use of alternative antiseptics, 
but more importantly universal versus targeted decolonisation strategies, will elucidate the 
effect of intensive use of chlorhexidine on emergence of resistance to antimicrobials and 
antiseptics in MRSA, MSSA and CoNS. 
 
 
11) Decolonisation agents for PVLPSA  (alternatives to chlorhexidine and mupirocin) 
 
To our knowledge, no decolonising agent has shown definite superior efficacy to 
chlorhexidine. However, an in vitro comparison has shown povidone-iodine and octenidine 
were superior to polyhexanide, chlorhexidine and triclosan (in decreasing order of efficacy) 
for immediate MRSA decolonisation [95] (Table 3).  
 
For nasal decolonisation mupirocin remains the drug of choice in hospital settings. It should 
be remembered though sustained use can lead to resistance and decolonisation failure. 
Page 11 of 23
Genetic determinants for resistance to mupirocin have been reported in PVLPSA. Therefore 
alternative regimens have been sought widely, although the superiority of these approaches in 
terms of MRSA eradication and long-term impact on emergence of resistance has not been 







PVL, a staphylococcal toxin known for 80 years and more intensively studied for the last 20 
years, remains an enigma. Why is the bacteriophage-encoded PVL frequently present among 
CA-MRSA strains while it is rare among many MSSA strains?  Clearly, it offers certain 
strains an evolutionary advantage. Further research is needed to understand fully the 
dynamics of PVL-bearing bacteriophage transmission among S. aureus strains, the global 
epidemiology of PVLPSA, and optimal strategies for the treatment, decolonization, 
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Table 1: Examples, pros, cons and potential indications for antimicrobials used in the treatment of 
PLVPSA  
Drug* Pros/Cons Clinical Use 
Antistaphylococcal β-
lactam (e.g., Oxacillin, 
flucloxacillin) 
Good tolerability profile/No PVL activity, 
no MRSA activity 
 
Use at highest possible dose  In combination when treating 




Good bioavailability and can be used as oral 
switch, effective against MSSA and MRSA 
when sensitive.  
Prolong use of these agents necessitate folinic acid 
supplements. Consider combination therapy with rifampicin.   
Vancomycin 
Anti-MRSA/ Slow bactericidal activity, i.v. 
only, renal toxicity 
 
Consider use in combination therapy (clindamycin or 




Good bone penetration, oral formulation/No 
PVL activity , limited tolerability (e.g., 
elderly); not ideal for  MRSA; concern for 
development of resistance on therapy 
Consider use in combination therapy e.g. with  rifampicin 
Doxycyline 
Good tolerability profile effective against 
MSSA and MRSA when sensitive. 
Can be used in combination with other agents (e.g. 
rifampicin)  
Rifampin 
Anti-MRSA and PVL activity, anti-biofilm 
activity/Resistance selection if used alone, 
drug-drug interactions, liver toxicity 
Should only be used  in combination therapy 
(fluoroquinolones for MSSA or a glycopeptide or daptomycin 
or fusidic acid for MRSA) 
Clindamycin 
Anti-PVL activity/ and MRSA when 
sensitive  
Use in combination treatment (e.g.,  β-lactam for MSSA or a 
glycopeptide or daptomycin for MRSA). 
Daptomycin 
Anti-MRSA, rapid bactericidal, anti-biofilm 
activity, good tolerability profile, once 
daily/Only i.v., high dose required (>8 
mg/kg) 
Use in combination therapy (clindamycin for MSSA or 
rifampicin for MSSA) 
 
 
Tigecycline Anti-MRSA/Only i.v. Use in polymicrobial infections 
Linezolid 
Anti-MRSA, anti-PVL activity, good bone 
penetration, oral formulation/Drug-drug 
interactions, toxicity for prolonged 
treatment 
 
Treatment of outpatients. Early oral switch  
Tedizolid** 
Anti-MRSA, anti-PVL activity, good bone 
penetration, oral formulation, once 
daily/High cost 
Treatment of outpatients 
*In general please follow local guidance and antimicrobial susceptibilities. Anti MRSA agents can also be used for MSSA if indicated. For 
uncomplicated SSTI combination treatment is seldom required.  
** There is limited clinical experience with this drug to date for complicated SSTIs and BJI.    
 
 
Page 21 of 23








Increased environmental cleaning, hand hygiene compliance along with either 
single room isolation or cohorting of affected patients, were first line precautions 
[77, 79]. Personal protective equipment (PPE) with contact precautions should be 
employed. Surgical masks and eye protection should be worn during aerosol 
generating procedures (e.g., nebulisers, intubation, airway suctioning) in patients 
with PVLPSA respiratory infections.The number of staff present should be limited 
to avoid unnecessary exposures. Additionally intra or inter hospital transport of 
affected patients should be limited. Exposed sites of colonisation, such as wounds 
and ulcers, should be covered with an occlusive dressing before leaving the ward.  
 
Excessive waiting times in departments should be minimized. Surfaces exposed to 
the patient or potentially contaminated secretions should be wiped down after use 
with frequent scheduled cleaning. On discharge, terminal environmental cleaning 
should be performed. Active screening followed by decolonization were 
additional measures [77]. Active screening proved effective when it included all 
patients at risk, all involved HCWs and patient family members, and colonized 
HCWs were excluded from the working environment pending successful 
decolonization [79]. Lee et al. implemented universal decolonization in order to 
curtail transmission of PVLPSA [78]. However, one should keep in mind that not 
all antiseptic substances and concentrations are suitable for pediatric patients.  
 
Staff with proven PVLPSA infection should be treated with appropriate 
antibiotics and should not return to work until infection has been eradicated. In the 
UK, Public Health England (PHE), recommends a topical five-day decolonization 
regimen for staff with proven PVLPSA infections commencing after all skin 
lesions are dry, and at least 48 hours prior to return to work. Weekly follow-up 
screens following topical decolonization are advised by the PHE [65, 66]. If the 
staff remains a carrier despite two courses of decolonisation treatment, the staff 
should be able to continue work provided they cease working as soon as possible 
if infected skin lesions recur. Routine screening of HCWs who have had contact 
with PVLPSA SSTI is not recommended unless active skin lesions or 
dermatological conditions are present. Staff exposed to respiratory secretions, e.g., 
intubation in PVLPSA necrotising pneumonias without appropriate PPE such as 
surgical face masks and eye protection, should be screened three to seven days 
after exposure and monitored for symptoms subsequently.  
 
 
Principles for preventing and controlling the spread of 
infection in the community setting centre on early 
suspicion of infection with rapid diagnosis, appropriate 
treatment and hygiene measures. Risk factors for 
transmission should be minimized. Hand hygiene 
should be emphasized with frequent and thorough 
cleaning with soap and water or alcohol based sanitizer. 
Personal items which may become contaminated (e.g., 
towels, clothing, bedding, bars of soap, razors) should 
not be shared. Clothing should be laundered in hot 
water and dried thoroughly [82, 84]. In athletes, 
strategies to minimize skin breaks, including prevention 
of turf burns [82], could also be considered. Individuals 
with active lesions may be advised to avoid use of 
shared sports equipment [84]. Environmental sanitation 
should be performed with scheduled cleaning of 
frequently touched surfaces. Users of shared 
equipment, e.g., exercise machines, should use clothing 
or towels to act as a barrier between surfaces of 
equipment and bare skin.  
 
Draining wounds should be kept covered with clean, 
dry dressings. Patients with open wounds should avoid 
recreational or communal activities involving skin-to-
skin contact until wounds are fully healed. Individual 
decolonisation therapy may be offered once the acute 
infection has resolved. Decolonization efforts in large 
community settings are of unclear benefit. However, 
exclusion of staff or members of a closed community, 
as well as screening confirmation of PVLPSA 
eradication, should be implemented on an 
individualised risk based approach, taking into 
consideration the severity of the infection in the 
outbreak, vulnerability of contacts in the setting, degree 
and nature of contact and risk of ongoing transmission 
despite general hygiene measures. 
Management of family outbreaks requires screening of 
the whole household (nose, groin and any skin lesions) 
for PVLPSA. The general principles of S. aureus control 
need to be employed [62]. Successful eradication requires 
rigorous attention to infection prevention principles 
within the family. These include initial management with 
early suspicion of infection, rapid diagnosis and 
appropriate treatment. Infected lesions must be covered 
with clean, dry dressings, which are changed as soon as 
discharge seeps to the surface.  
 
Evidence for prevention is limited specifically for 
PVLPSA. Once confirmed, personal hygiene and good 
skin care (particularly those with eczema) should be 
encouraged. Use of separate towels, not sharing personal 
items such as razors, toothbrushes, and face cloths, and 
ensuring laundry of towels, bed linen, and clothing using 
a hot wash (60oC) are recommended where possible 
[85,86]. The household should be cleaned regularly with 
vacuuming and dusting [58]. Household pets have 
occasionally been implicated in persisting PVLPSA 
(please refer to topic 7 and 8 of this manuscript) 
 
Infected householders should be advised to avoid 
communal and recreational settings until lesions are 
healed if they cannot be adequately contained by a 
dressing. 
 
Those who work in occupations where they might pose a 
risk of infection to others, such as HCWs, carers in 
nurseries, residential or care homes or similar, or food 
handlers, should be excluded from work until the lesions 
have healed. 
 
Limited data support performing initial eradication in all 
household members , however this can be offered. 
Quarterly decolonization has been proposed in refractory 
or recurrent PVLPSA colonization and infections among 
families [67]. Further studies are required to support these 
suggestions and proposals.   
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Table 3: Alternative agents proposed for skin and nasal decolonisation 
Proposed use Agent Decolonisation rates relative to placebo or 
gold standard agents 
Resistance 






Polyhexadine  96 Clinical trial of a single decolonisation course 
with polyhexadine was not more efficacious 
than the placebo in eradication of MRSA.  
None identified  None in most 
studies  
Octenidine 97 Placebo-controlled efficacy comparable to 
chlorhexidine, but the 2 agents not yet 
compared in RCT  
None identified  Inconsistent data 
across studies  
Tea tree oil 98 Eradication rates comparable to chlorhexidine-
based treatments (small trial) 
Not investigated Further studies 
required; concern 




More efficacious than chlorhexidine in 
eradication. Currently recommended by the 
Infectious Diseases Society of America for 
prevention of recurrence of MRSA-related skin 
infections.   
None identified  Dry skin 
Hexachlorophene 
100 
Narrow-spectrum agents such as the Gram-
positive specific hexachlorophene may be 
useful for targeted decolonisation approaches. 
Not more efficacious than placebo  
Not investigated Systemic 
absorption leading 
to neurotoxicity 





 SHRO102 Excellent activity against Gram positive 
organisms including MRSA as well as Gram 
negatives, however there are no RCTs to 
determine superiority to mupirocin or other 
agents.  
 





polymyxin B) 103 
Less efficacious than mupirocin  Multiple mechanisms 
identified 
High prevalence of 
contact dermatitis  
Tea tree oil 98 Less efficacious than mupirocin  Not investigated  Further studies 
required 
SHRO 102 No comparator studies been done with 
mupirocin.  
Not known  Rare  
Pleuromutulins 
104 
More potent than mupirocin in vitro  but the 2 




Lauric acid 105 More efficacious than mupirocin in a 
preclinical model, but the 2 agents not yet 
compared in RCT 
Not investigated Not assessed in 
clinical studies 
Lytic phage 106, 
107 
More efficacious than mupirocin in a 
preclinical model, but the 2 agents not yet 
compared in RCT. The breadth of action across 
clinical isolates of genus-specific approaches 
such as obligate lytic phage is yet to be 
demonstrated 
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